Naturally occurring antimitotic pentapeptide dolastatin 10 (1, Figure 1)[1] and its synthetic
analogue auristatin E (AE, 2)[2] possess subnanomolar cytotoxicity against many human …

Despite promising early data, the natural product dolastatin 10 has not been successful as a
single agent in phase II clinical trials. Herein the mechanism of action and efficacy of a …

Novel monomethylauristatin E (MMAE) prodrug 8 was designed and prepared that bound
cell surface glycoprotein integrin αvβ3, and was activated using legumain protease as a …

Auristatins are highly potent antimitotic agents that have received considerable attention
because of their activities when targeted to tumor cells in the form of antibody− drug …

Auristatins, synthetic analogues of the antineoplastic natural product Dolastatin 10, are
ultrapotent cytotoxic microtubule inhibitors that are clinically used as payloads in antibody …

We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug
conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and …

Auristatins are important payloads used in antibody drug conjugates (ADCs), and the most
well-known compound family member, monomethyl auristatin (MMAE), is used in two Food …

Auristatins are a class of highly cytotoxic tubulin-disrupting peptides, which have shown
limited therapeutic effect as free agents in clinical trials. In our continuing effort to develop …

Dolastatin 10 is a powerful antineoplastic agent and microtubule inhibitor that was
discovered by Pettit et al. and published in 1987. Since then, many research groups have …

Antibody drug conjugates offer a targeted cancer treatment for the delivery of potent
cytotoxic drugs. Derivatives of the natural product dolastatin 10 containing pyridines and …